IKS - Fundamental Analysis: Financial Health & Valuation

Last Updated Time : 19 Sept 25, 2:16 pm

🧠 My Thought Process

You're asking for a full-spectrum fundamental analysis of Inventurus Knowledge Solutions Ltd (IKS), with a numeric rating and strategic investment guidance. I’ve weighed profitability, capital efficiency, valuation, and business durability, and incorporated recent analyst targets, institutional sentiment, and technical signals as of September 2025.

📊 Fundamental Analysis of IKS

🔍 Core Financials

Profitability

PAT Qtr: ₹113 Cr vs ₹99.8 Cr — strong sequential growth (↑97.3% YoY).

EPS: ₹22.6 — solid, supported by high-margin operations.

ROE: 32.3%, ROCE: 35.0% — excellent capital efficiency, well above industry norms.

Leverage & Liquidity

Debt-to-equity: 0.06 — virtually debt-free, strong balance sheet.

Dividend Yield: 0.00% — reinvestment-focused, no payouts yet.

Cash Flow & Stability

FY24 revenue: ₹1,818 Cr; net income: ₹370 Cr

1

.

Promoter: Rakesh Jhunjhunwala family — adds credibility and long-term vision.

Strong institutional interest: FII ↑1.12%, DII ↑0.31%.

📉 Valuation Indicators

Metric Value Interpretation

P/E Ratio 68.1 Overvalued vs industry PE of 32.2

P/B Ratio ~21.5 High — reflects premium on brand and scalability

PEG Ratio 3.92 Elevated — growth not fully justifying price

Intrinsic Value ~₹1,450–₹1,500 Slightly below current price — limited upside

🏥 Business Model & Competitive Edge

Segment Focus: Healthcare IT services — revenue cycle management, clinical documentation, and value-based care.

Moat: Deep integration with US healthcare providers, proprietary platforms, and high switching costs.

Growth Drivers

Global expansion and digital transformation in healthcare.

AI-driven automation and analytics for hospitals and clinics.

Analyst consensus target: ₹1,820 — ~15% upside from current levels

2

.

📈 Technical & Entry Guidance

Current Price: ₹1,540

DMA 50/200: ₹1,571 / ₹1,658 — trading below long-term average, indicating consolidation.

RSI: 45.5 — mildly oversold.

MACD: -7.14 — bearish crossover.

🎯 Entry Zone

Ideal Buy Range: ₹1,480–₹1,520 — near support and intrinsic value.

Stop Loss: ₹1,425

Target: ₹1,820–₹1,900 in medium term

🕰️ Long-Term Holding Outlook

Hold if invested: Strong fundamentals, global moat, and promoter pedigree support long-term value.

Buy on dips: Preferably near ₹1,500 zone.

Growth Triggers: US healthcare digitization, AI adoption, and analyst upgrades.

⭐ Fundamental Rating

4.2

1

tradewatch360.com

2

trendlyne.com

Edit in a page